Tempest Therapeutics Secures $2.0M in Private Placement, Potentially $6.0M with Warrants

summarizeSummary

Tempest Therapeutics entered into a private placement agreement to raise $2.0 million initially, with the potential for an additional $4.0 million upon warrant exercise, to fund working capital and general corporate purposes.

check_boxKey Events

• Private Placement Agreement

  Tempest Therapeutics entered into a securities purchase agreement on March 20, 2026, for a private placement with two institutional investors and a strategic investor.

• Initial Capital Raise

  The company expects to receive approximately $2.0 million in gross proceeds from the sale of 462,964 shares of common stock and up to 462,963 pre-funded warrants.

• Potential Additional Funding

  Up to an additional $4.0 million in gross proceeds may be received in the future upon the cash exercise of accompanying Series A and Series B warrants.

• Securities Issued

  The offering includes common stock, pre-funded warrants (exercisable at $0.001 per share), and 1,851,854 common warrants (exercisable at $2.16 per share).

auto_awesomeAnalysis

This financing event provides Tempest Therapeutics with crucial capital, addressing immediate working capital needs for this nano-cap life sciences company. While the offering involves significant potential dilution through the issuance of common stock and warrants, the initial $2.0 million raise, with a potential total of $6.0 million, is substantial relative to the company's market capitalization. The pricing of the shares and warrants is close to the current market price, which is a more favorable term than deep discount offerings often seen in distressed situations. The requirement for stockholder approval for the common warrants introduces a future contingency, but the company's commitment to seeking it is noted. Investors should monitor the outcome of the stockholder vote and the subsequent exercise of warrants, as full exercise would significantly increase the outstanding share count.